Globeflex Capital L P Sells 5,186 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Globeflex Capital L P lessened its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 8.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 54,858 shares of the biotechnology company's stock after selling 5,186 shares during the period. United Therapeutics accounts for approximately 1.6% of Globeflex Capital L P's portfolio, making the stock its 13th largest holding. Globeflex Capital L P owned approximately 0.12% of United Therapeutics worth $19,356,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics in the 4th quarter worth approximately $25,000. Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the 3rd quarter worth $33,000. MassMutual Private Wealth & Trust FSB grew its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 58 shares in the last quarter. Jones Financial Companies Lllp increased its stake in United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after acquiring an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in United Therapeutics during the fourth quarter valued at about $131,000. Institutional investors own 94.08% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on UTHR. HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, UBS Group upped their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $388.25.

Remove Ads

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares of the company's stock, valued at approximately $929,678.52. This represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Louis W. Sullivan sold 26,209 shares of the firm's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total value of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 116,464 shares of company stock worth $42,396,244 over the last three months. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

Shares of UTHR traded down $2.71 on Tuesday, reaching $320.24. The company's stock had a trading volume of 150,407 shares, compared to its average volume of 442,806. The stock's 50 day simple moving average is $349.12 and its two-hundred day simple moving average is $358.27. The stock has a market capitalization of $14.38 billion, a P/E ratio of 14.06, a PEG ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million for the quarter, compared to analysts' expectations of $734.74 million. During the same period last year, the firm earned $4.36 EPS. Analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.